KR101760277B1 - Ｔ-세포 수용체 - Google Patents

Ｔ-세포 수용체 Download PDF

Info

Publication number
KR101760277B1
KR101760277B1 KR1020127009216A KR20127009216A KR101760277B1 KR 101760277 B1 KR101760277 B1 KR 101760277B1 KR 1020127009216 A KR1020127009216 A KR 1020127009216A KR 20127009216 A KR20127009216 A KR 20127009216A KR 101760277 B1 KR101760277 B1 KR 101760277B1
Authority
KR
South Korea
Prior art keywords
leu
amino acid
tcr
cell
ebv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127009216A
Other languages
English (en)
Korean (ko)
Other versions
KR20120074291A (ko
Inventor
한스 스타우스
샤오-안 수
막스 토프
Original Assignee
유씨엘 비즈니스 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유씨엘 비즈니스 피엘씨 filed Critical 유씨엘 비즈니스 피엘씨
Publication of KR20120074291A publication Critical patent/KR20120074291A/ko
Application granted granted Critical
Publication of KR101760277B1 publication Critical patent/KR101760277B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020127009216A 2009-09-29 2010-09-28 Ｔ-세포 수용체 Expired - Fee Related KR101760277B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0917090.3A GB0917090D0 (en) 2009-09-29 2009-09-29 T-cell receptor
GB0917090.3 2009-09-29
PCT/GB2010/001821 WO2011039508A2 (en) 2009-09-29 2010-09-28 T-cell receptor

Publications (2)

Publication Number Publication Date
KR20120074291A KR20120074291A (ko) 2012-07-05
KR101760277B1 true KR101760277B1 (ko) 2017-07-21

Family

ID=41350560

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127009216A Expired - Fee Related KR101760277B1 (ko) 2009-09-29 2010-09-28 Ｔ-세포 수용체

Country Status (10)

Country Link
US (1) US8889141B2 (cg-RX-API-DMAC10.html)
EP (1) EP2483294B1 (cg-RX-API-DMAC10.html)
JP (2) JP6180114B2 (cg-RX-API-DMAC10.html)
KR (1) KR101760277B1 (cg-RX-API-DMAC10.html)
CN (1) CN102695717B (cg-RX-API-DMAC10.html)
AU (1) AU2010302477B2 (cg-RX-API-DMAC10.html)
ES (1) ES2584541T3 (cg-RX-API-DMAC10.html)
GB (1) GB0917090D0 (cg-RX-API-DMAC10.html)
IN (1) IN2012DN02993A (cg-RX-API-DMAC10.html)
WO (1) WO2011039508A2 (cg-RX-API-DMAC10.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
EP2694640B1 (en) 2011-04-08 2017-10-18 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
RS61455B1 (sr) 2011-10-28 2021-03-31 Regeneron Pharma Genetski modifikovani miševi t ćelijskog receptora
BR112014014591A8 (pt) 2011-12-12 2017-07-04 Baylor College Medicine processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
EP3495483A1 (en) 2012-09-12 2019-06-12 International Institute of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
CN110511960B (zh) * 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
PT3149031T (pt) * 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
WO2015199618A1 (en) * 2014-06-24 2015-12-30 National University Of Singapore Epstein-barr virus lmp2 specific antibody and uses thereof
PL3212225T3 (pl) 2014-10-31 2026-03-30 The Trustees Of The University Of Pennsylvania Sposoby i kompozycje zmodyfikowanych limfocytów t
WO2016095783A1 (zh) * 2014-12-17 2016-06-23 中国科学院广州生物医药与健康研究院 识别eb病毒短肽的t细胞受体
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
MX2017012829A (es) 2015-04-06 2018-02-23 Regeneron Pharma Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
CN104830793A (zh) * 2015-05-05 2015-08-12 杨光华 基于lmp-1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途
IL281396B (en) * 2015-06-09 2022-07-01 Memorial Sloan Kettering Cancer Center T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
KR101794304B1 (ko) 2015-09-01 2017-11-06 가톨릭대학교 산학협력단 Ｅｂｖ 항원 특이 ｔ―세포 수용체 및 이의 용도
US11167024B2 (en) 2015-09-18 2021-11-09 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
GB201520191D0 (en) * 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
CN109963860A (zh) * 2016-09-19 2019-07-02 拜耳作物科学股份公司 吡唑并[1,5-a]吡啶衍生物及其作为农药的用途
CN108218976B (zh) * 2016-12-09 2021-11-05 香雪生命科学技术（广东）有限公司 衍生自lmp1的肿瘤抗原短肽
WO2019031938A2 (ko) 2017-08-10 2019-02-14 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
EP3773633A4 (en) 2018-04-06 2022-01-26 The Regents of The University of California METHODS OF TREATMENT OF GLIOBLASTOMA
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
SG11202101671PA (en) 2018-11-27 2021-03-30 Univ Duke Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers
WO2020133050A1 (zh) * 2018-12-27 2020-07-02 深圳华大生命科学研究院 Ebv表位高亲和力t细胞受体
EP3786178A1 (en) * 2019-08-30 2021-03-03 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for ebv-derived antigens
WO2021211455A1 (en) * 2020-04-13 2021-10-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against lmp2
WO2021243695A1 (en) * 2020-06-05 2021-12-09 Guangdong Tcrcure Biopharma Technology Co., Ltd. Tcr-t cell therapy targeting epstein-barr virus
EP3940075A1 (en) * 2020-07-17 2022-01-19 Istituto Nazionale Di Genetica Molecolare-INGM Inhibitors of line1 and uses thereof
CN116981357A (zh) 2021-03-31 2023-10-31 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
CN113773378B (zh) * 2021-10-14 2023-11-03 深圳大学总医院 T细胞受体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101182531B (zh) * 2007-11-09 2010-06-02 暨南大学 Eb病毒特异性tcr基因相关的重组质粒及构建抗ebv特异性ctl的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DP Hart 등. Gene Therapy. Vol. 15, No. 8, 페이지 625-631 (2008.)*
Hans J Stauss 등. Molecular Therapy. Vol. 15, No. 10, 페이지 1744-1750 (2007.)*
Lisa A. Jurgens 등. Journal of Clinical Immunology. Vol. 26, No. 1, 페이지 22-32 (2006.)*

Also Published As

Publication number Publication date
US20120244132A1 (en) 2012-09-27
EP2483294B1 (en) 2016-07-13
CN102695717B (zh) 2016-08-10
GB0917090D0 (en) 2009-11-11
JP2016047064A (ja) 2016-04-07
IN2012DN02993A (cg-RX-API-DMAC10.html) 2015-07-31
AU2010302477B2 (en) 2017-01-19
US8889141B2 (en) 2014-11-18
WO2011039508A3 (en) 2011-06-30
EP2483294A2 (en) 2012-08-08
WO2011039508A2 (en) 2011-04-07
JP2013505734A (ja) 2013-02-21
AU2010302477A1 (en) 2012-04-19
CN102695717A (zh) 2012-09-26
JP6180114B2 (ja) 2017-08-16
ES2584541T3 (es) 2016-09-28
KR20120074291A (ko) 2012-07-05

Similar Documents

Publication Publication Date Title
EP2483294B1 (en) T-cell receptor
EP2483303B1 (en) T-cell receptor capable of recognising an antigen from cytomegalovirus
DK2288700T3 (en) HBV EPITOP-REACTIVE EXOGEN T-CELL RECEPTOR (TCR) AND APPLICATIONS THEREOF
CN108026151B (zh) Pd-1-cd28融合蛋白及其在医学中的用途
EP3615565A1 (en) Tcr and peptides
WO2020089433A2 (en) Tcr and peptides
AU2017205637A1 (en) Compositions and libraries comprising recombinant T-cell receptors and methods of using recombinant T-cell receptors
CN102272153A (zh) 高亲和力t细胞受体及其应用
CN112166193A (zh) 具有经修饰的接头结构域的嵌合抗原受体及其用途
WO2016095783A1 (zh) 识别eb病毒短肽的t细胞受体
WO2021163434A1 (en) Hla class i-restricted t cell receptors against ras with g12d mutation
JP2024019533A (ja) 膜結合型ＩＬ－１０を発現する遺伝子的にリプログラミングされたＴｒｅｇ
WO2021211455A1 (en) Hla class i-restricted t cell receptors against lmp2
CN110272482A (zh) 识别prame抗原短肽的t细胞受体
KR101794304B1 (ko) Ｅｂｖ 항원 특이 ｔ―세포 수용체 및 이의 용도
WO2018077242A1 (zh) 识别sage1抗原短肽的t细胞受体
CN115786268A (zh) 工程化免疫细胞及其用途
EP4328239A1 (en) Immunotherapeutics based on magea1-derived epitopes
US20230312672A1 (en) Hla class i-restricted t cell receptors against cd20
HK40064520B (en) Pd1-cd28 fusion proteins and their use in medicine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200718

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200718

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000